Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer

Fig. 1

CTX-HSA-NPs combined with TGFβ-1 siRNA LNP for the treatment of paclitaxel-resistant NSCLC. Cabazitaxel is a taxane antineoplastic agent that promotes the assembly of microtubule doublets into microtubules by binding to tubulin, while at the same time stabilizing microtubules by preventing their disassembly through the depolymerization process, thereby affecting mitotic and interphase cell function and inhibiting cancer cell proliferation. CTX-HSA-NPs were prepared by HSA loading of cabazitaxel. TGFβ-1 siRNA LNP were prepared by microfluidic mixing of siRNA with 4 lipids (1,2-Dioctadecanoyl-sn-glycero-3-phophocholine (DSPC), (6Z,9Z,28Z,31Z)-heptatriacont-6,9,28,31-tetraene-19-yl 4-(dimethylamino) butanoate (DLin-MC3-DMA), 1,2-dimyristoyl-rac-glycero-3-carbonylaminomethyl-ω-methoxypolyethylene glycol-2000 (PEG2000-c-DMG) and cholesterol). Combination of CTX-HSA-NPs and TGFβ-1 siRNA LNP in the treatment of paclitaxel-resistant NSCLC. TGFβ-1 siRNA LNP enters the cytoplasm and releases TGFβ-1 siRNA, which acts on the target TGFβ-1 mRNA and prevents the mRNA from being translated into protein. The expression level of TGFβ-1 is reduced and the growth of A549/T cells is inhibited. CTX-HSA-NPs is released from HSA after entering cells to kill A549/T cells

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us